CLINICAL RESEARCH & TRIALS

Clinical Trial Site Selection Study

Sponsors, CROs, and site networks evaluate feasibility signals, patient recruitment capacity, and investigator readiness across candidate sites, so you can sharpen site activation timelines, reduce screen failure rates, and benchmark portfolio allocation by therapeutic area.

Multi-country sample
Clinical site teams (Principal Investigators, Site Directors)
15-20 min
Talk to a Survey Consultant
Site activation frictionIdentify where feasibility gaps, IRB delays, or staffing constraints stall site activation.
Selection drivers & trade-offsRank patient access, infrastructure readiness, and protocol complexity against sponsor priorities.
TRUSTED BY LEADING BRANDS
Brand 0Brand 1Brand 2Brand 3Brand 4Brand 5Brand 6Brand 7Brand 8Brand 9Brand 10Brand 11Brand 12Brand 13Brand 14Brand 15Brand 16Brand 17Brand 18Brand 19Brand 20Brand 21Brand 22Brand 23Brand 24Brand 25Brand 26Brand 27Brand 28Brand 29Brand 30Brand 31

CONTEXT & RELEVANCE

Why run this survey now

Most sponsors don't lose trial timelines purely on patient recruitment speed. They lose them due to investigator capability gaps, site infrastructure mismatches, regulatory readiness shortfalls, patient population misalignment, and protocol complexity fit failures, none of which fully show up in feasibility questionnaires or site performance databases.

If you are...

  • Sponsor site selection lead
  • CRO feasibility and operations head
  • Clinical development VP
  • Regulatory and site activation director
  • Trial portfolio strategy lead

You're likely facing...

  • Site capability vs. protocol fit gap
  • Enrollment delays: activation to first patient
  • Established sites = reliable but slow
  • New sites = fast but under-vetted
  • Retention drop-off mid-trial

This will help answer...

  • Site selection criteria by indication
  • Activation-to-enrollment delay drivers
  • Investigator experience tier segmentation
  • Budget vs. site quality trade-offs
  • Dropout and retention risk signals

RESEARCH THEMES

What This Survey Investigates

Eight interconnected research themes that map the complete site selection journey from feasibility assessment to site performance closeout.

TENETS 01

Site Discovery & Sourcing

  • Sponsor-initiated vs. CRO-led sourcing
  • Feasibility outreach channels used
TENETS 02

Feasibility & Selection

  • Feasibility questionnaire burden and turnaround
  • Selection criteria ranked by sponsors
TENETS 03

Regulatory & IRB Readiness

  • IRB submission timelines by site type
  • Regulatory bottlenecks at activation
TENETS 04

Contract & Budget Friction

  • Cycle time from LOI to executed CTA
  • Budget negotiation sticking points
TENETS 05

Patient Recruitment & Retention

  • Enrollment rate vs. projected targets
  • Screen failure and dropout drivers
TENETS 06

Site Staff & Capacity

  • Coordinator-to-trial ratio and burnout signals
  • Training burden per new protocol
TENETS 07

Technology & Data Systems

  • EDC and CTMS adoption by site tier
  • Interoperability gaps with sponsor platforms
TENETS 08

Sponsor & CRO Relations

  • CRA visit frequency and oversight burden
  • Sponsor preference: large network vs. independent

SAMPLING STRATEGY

Tell us about your ideal sample

Help us understand your target respondent profile. Select what applies, we'll design the optimal sample plan based on your inputs.

Sample size
How many respondents do you need?
Not Selected
Target audience
Who should we survey?
Not Selected
Region
Which regions should we cover?
Not Selected
Segments
How should we slice the data?
Not Selected
Discuss sample plan

METHODOLOGY

Survey approach

For the Clinical Trial Site Selection Study, we recommend a quant-first design with flexible data-collection modes to balance reach, depth, and verification across investigator sites and sponsor teams.

PRIMARY
Online web surveySelf-administered survey shared via email / panels to capture structured responses at scale.
Best for
1
Ranking site selection criteria by sponsor priority
2
Benchmarking site readiness across therapeutic areas
3
Comparing investigator profiles by region and indication
Deliverables
Site criteria rankings
Readiness gap matrix
Sponsor preference bands
OPTIONAL
CATI (phone survey)Interviewer-led telephone interviews to reach owners who are harder to get online.
Best for
1
Principal investigators with low digital survey engagement
2
Rapid coverage across multiple trial sites or geographies
Deliverables
Investigator coverage data
Call-log diagnostics
SELECTIVE
Face-to-faceOn-ground surveys or interviews in key industrial clusters or high-value cohorts.
Best for
1
High-enrolling sites requiring in-depth feasibility verification
2
Contextual mapping of local patient recruitment ecosystems
Deliverables
Site feasibility profiles
Recruitment ecosystem maps
OPTIONAL
FGDs
Deliverables
Themes and quotes
Framework feedback
OPTIONAL
Mixed surveysAny 4-mode combo Online + CATI + F2F + FGDs to maximise reach and representation. Mode-specific quotas and weighting for clean comparisons.
Deliverables
Unified dataset
Mode-adjusted analytics
Our Recommendation
Start with: Online web survey as the core quantitative layer, targeting sponsors, CROs, and site coordinators across key therapeutic areas and geographies.
Consider adding: CATI for principal investigators with low digital engagement, and F2F interviews at high-enrolling sites where feasibility verification and recruitment ecosystem mapping require on-ground presence.

EXECUTION PROCESS

How we execute

A proven 9-step process from scoping to delivery, designed to ensure quality, speed, and actionable insights.

Define the decision frame

Confirm objectives, target cohorts, geographies, and reporting cuts

Step 01

Define the decision frame

Design the instrument

Build workstream modules mapped to outputs (drivers, friction, pricing, retention, trust)

Step 02

Design the instrument

Lock the questionnaire

Review wording, sequencing, LOI, and competitive context; approve final version

Step 03

Lock the questionnaire

Pilot and calibrate

Test comprehension and ease quality; refine quotas and remove friction where needed

Step 04

Pilot and calibrate

Run fieldwork

Execute collection with active quota management and feasibility controls

Step 05

Run fieldwork

Assure quality

Dedupe, attention checks, speed/consistency rules, removals with audit trail

Step 06

Assure quality

Prepare the dataset

Clean data and deliver codebook/variable definitions

Step 07

Prepare the dataset

Analyse and synthesise

Driver ranking, leakage diagnostics, pricing bands, segment insights

Step 08

Analyse and synthesise

Deliver and align

Executive deck (optional dashboard) and leadership readout with recommendations

Step 09

Deliver and align

COMMERCIAL TERMS

Request a Commercial Proposal

Pricing depends on cohort, geography, sample size, approach, LOI, and deliverables. Configure below for an indicative estimate.

Select Sample Size

100

Geography

  • India
  • APAC (Singapore, Vietnam, Philippines, Indonesia, Australia, NZ, Japan, Thailand)
  • Middle East (UAE, KSA, Qatar, Bahrain, Oman, Kuwait)
  • North America (US, Canada)
  • Europe
  • Africa (South Africa, Kenya, Nigeria, Egypt, Algeria)
  • LATAM (Brazil, Mexico)

Select Mode of Survey

  • Online
  • CATI
  • Online FGD (5 people per FGD)
  • F2F

Length of the Interview

  • Select
  • 0-15
  • 16-20
  • 21-30
  • 31-45
  • 46-60
  • Custom
Indicative Estimate
  • Indian Rupee (INR)
  • United Arab Emirates Dirham (AED)
  • Afghan Afghani (AFN)
  • Albanian Lek (ALL)
  • Armenian Dram (AMD)
  • Netherlands Antillean Guilder (ANG)
  • Angolan Kwanza (AOA)
  • Argentine Peso (ARS)
  • Australian Dollar (AUD)
  • Aruban Florin (AWG)
  • Azerbaijani Manat (AZN)
  • Bosnia-Herzegovina Convertible Mark (BAM)
  • Barbadian Dollar (BBD)
  • Bangladeshi Taka (BDT)
  • Bulgarian Lev (BGN)
  • Bahraini Dinar (BHD)
  • Burundian Franc (BIF)
  • Bermudian Dollar (BMD)
  • Brunei Dollar (BND)
  • Bolivian Boliviano (BOB)
  • Brazilian Real (BRL)
  • Bahamian Dollar (BSD)
  • Bhutanese Ngultrum (BTN)
  • Botswana Pula (BWP)
  • Belarusian Ruble (BYN)
  • Belize Dollar (BZD)
  • Canadian Dollar (CAD)
  • Congolese Franc (CDF)
  • Swiss Franc (CHF)
  • Chilean Peso (CLP)
  • Chinese Yuan (CNY)
  • Colombian Peso (COP)
  • Costa Rican Colón (CRC)
  • Cuban Peso (CUP)
  • Cape Verdean Escudo (CVE)
  • Czech Koruna (CZK)
  • Djiboutian Franc (DJF)
  • Danish Krone (DKK)
  • Dominican Peso (DOP)
  • Algerian Dinar (DZD)
  • Egyptian Pound (EGP)
  • Eritrean Nakfa (ERN)
  • Ethiopian Birr (ETB)
  • Euro (EUR)
  • Fijian Dollar (FJD)
  • Falkland Islands Pound (FKP)
  • British Pound (GBP)
  • Georgian Lari (GEL)
  • Ghanaian Cedi (GHS)
  • Gibraltar Pound (GIP)
  • Gambian Dalasi (GMD)
  • Guinean Franc (GNF)
  • Guatemalan Quetzal (GTQ)
  • Guyanese Dollar (GYD)
  • Hong Kong Dollar (HKD)
  • Honduran Lempira (HNL)
  • Croatian Kuna (HRK)
  • Haitian Gourde (HTG)
  • Hungarian Forint (HUF)
  • Indonesian Rupiah (IDR)
  • Israeli New Shekel (ILS)
  • Iraqi Dinar (IQD)
  • Iranian Rial (IRR)
  • Icelandic Króna (ISK)
  • Jamaican Dollar (JMD)
  • Jordanian Dinar (JOD)
  • Japanese Yen (JPY)
  • Kenyan Shilling (KES)
  • Kyrgyzstani Som (KGS)
  • Cambodian Riel (KHR)
  • Comorian Franc (KMF)
  • South Korean Won (KRW)
  • Kuwaiti Dinar (KWD)
  • Cayman Islands Dollar (KYD)
  • Kazakhstani Tenge (KZT)
  • Lao Kip (LAK)
  • Lebanese Pound (LBP)
  • Sri Lankan Rupee (LKR)
  • Liberian Dollar (LRD)
  • Lesotho Loti (LSL)
  • Libyan Dinar (LYD)
  • Moroccan Dirham (MAD)
  • Moldovan Leu (MDL)
  • Malagasy Ariary (MGA)
  • Macedonian Denar (MKD)
  • Burmese Kyat (MMK)
  • Mongolian Tögrög (MNT)
  • Macanese Pataca (MOP)
  • Mauritian Rupee (MUR)
  • Maldivian Rufiyaa (MVR)
  • Malawian Kwacha (MWK)
  • Mexican Peso (MXN)
  • Malaysian Ringgit (MYR)
  • Mozambican Metical (MZN)
  • Namibian Dollar (NAD)
  • Nigerian Naira (NGN)
  • Nicaraguan Córdoba (NIO)
  • Norwegian Krone (NOK)
  • Nepalese Rupee (NPR)
  • New Zealand Dollar (NZD)
  • Omani Rial (OMR)
  • Panamanian Balboa (PAB)
  • Peruvian Sol (PEN)
  • Papua New Guinean Kina (PGK)
  • Philippine Peso (PHP)
  • Pakistani Rupee (PKR)
  • Polish Złoty (PLN)
  • Paraguayan Guaraní (PYG)
  • Qatari Riyal (QAR)
  • Romanian Leu (RON)
  • Serbian Dinar (RSD)
  • Russian Ruble (RUB)
  • Rwandan Franc (RWF)
  • Saudi Riyal (SAR)
  • Solomon Islands Dollar (SBD)
  • Seychellois Rupee (SCR)
  • Sudanese Pound (SDG)
  • Swedish Krona (SEK)
  • Singapore Dollar (SGD)
  • Saint Helena Pound (SHP)
  • Sierra Leonean Leone (SLL)
  • Somali Shilling (SOS)
  • Surinamese Dollar (SRD)
  • São Tomé and Príncipe Dobra (STD)
  • Syrian Pound (SYP)
  • Swazi Lilangeni (SZL)
  • Thai Baht (THB)
  • Tajikistani Somoni (TJS)
  • Turkmenistani Manat (TMT)
  • Tunisian Dinar (TND)
  • Tongan Paʻanga (TOP)
  • Turkish Lira (TRY)
  • Trinidad and Tobago Dollar (TTD)
  • New Taiwan Dollar (TWD)
  • Tanzanian Shilling (TZS)
  • Ukrainian Hryvnia (UAH)
  • Ugandan Shilling (UGX)
  • United States Dollar (USD)
  • Uruguayan Peso (UYU)
  • Uzbekistani Som (UZS)
  • Vietnamese Đồng (VND)
  • Vanuatu Vatu (VUV)
  • Samoan Tālā (WST)
  • Central African CFA Franc (XAF)
  • East Caribbean Dollar (XCD)
  • West African CFA franc (XOF)
  • CFP Franc (XPF)
  • Yemeni Rial (YER)
  • South African Rand (ZAR)
  • Zambian Kwacha (ZMW)
  • Zimbabwean Dollar (ZWL)

$0.00

+ applicable taxes

Proposal turnaround typically 24–48 hours

Note: Estimate is indicative only. Final pricing is subject to scope finalization after discovery call.

REFERENCE CASELETS

Reference

Real-world examples of survey work in the clinical research site operations space.

CASELET 1

Investigator site capacity & feasibility perception mapping (India)

CASELET 2

Sponsor preference & site retention drivers among oncology investigators (Southeast Asia)

Investigator site capacity & feasibility perception mapping (India)

OBJECTIVE

A specialty CRO needed to map how principal investigators and site coordinators at tier-2 hospital sites evaluate feasibility commitments, assess protocol complexity, and decide whether to accept or decline incoming trial mandates.

WHAT WE DID

Ran a structured quant survey across 120 site staff spanning 6 therapeutic areas, capturing protocol review time, patient recruitment confidence scores, IRB turnaround expectations, and sponsor communication frequency preferences by site tier and staff seniority.

DELIVERED

A site feasibility perception map by therapeutic area, a ranked friction list across the pre-activation window, and a site readiness segment framework separating high-capacity sites from structurally constrained ones across 4 distinct profiles.
CASELET 1

Investigator site capacity & feasibility perception mapping (India)

CASELET 2

Sponsor preference & site retention drivers among oncology investigators (Southeast Asia)

Investigator site capacity & feasibility perception mapping (India)

OBJECTIVE

A specialty CRO needed to map how principal investigators and site coordinators at tier-2 hospital sites evaluate feasibility commitments, assess protocol complexity, and decide whether to accept or decline incoming trial mandates.

WHAT WE DID

Ran a structured quant survey across 120 site staff spanning 6 therapeutic areas, capturing protocol review time, patient recruitment confidence scores, IRB turnaround expectations, and sponsor communication frequency preferences by site tier and staff seniority.

DELIVERED

A site feasibility perception map by therapeutic area, a ranked friction list across the pre-activation window, and a site readiness segment framework separating high-capacity sites from structurally constrained ones across 4 distinct profiles.

FREQUENTLY ASKED QUESTIONS

Common Questions

Answers to frequently asked questions about this survey mandate.

What decisions will this survey enable?

Who is the buyer vs who are the respondents?

Can we see differences between academic medical centers, independent research sites and hybrid network sites?

How will you measure site selection preference beyond simple ratings?

Will the survey map the full site qualification journey and drop-offs?

Can this survey inform product and pricing strategy?

How will findings improve our site activation and enrollment performance?

Still have questions?

Schedule a discovery call to discuss your specific needs and get a custom quote.

Book a Discovery Call